Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study

来那度胺 医学 美罗华 弥漫性大B细胞淋巴瘤 伊布替尼 内科学 临床终点 临床研究阶段 肿瘤科 淋巴瘤 胃肠病学 外科 临床试验 多发性骨髓瘤 慢性淋巴细胞白血病 白血病
作者
Pengpeng Xu,Zi‐Yang Shi,Ying Qian,Shu Cheng,Yue Zhu,Lu Jiang,Jianfeng Li,Hai Fang,Hengye Huang,Hongmei Yi,Bin-Sheng Ouyang,Li Wang,Weili Zhao
出处
期刊:The Lancet Healthy Longevity [Elsevier BV]
卷期号:3 (7): e481-e490 被引量:27
标识
DOI:10.1016/s2666-7568(22)00123-4
摘要

The optimal treatment for older adults with diffuse large B-cell lymphoma (DLBCL) needs to be further explored due to patient comorbidities, standard immunochemotherapy intolerance, and unfavourable genetic features. We did a phase 2 trial of ibrutinib, rituximab, and lenalidomide (iR2) to evaluate the efficacy and safety in older adult patients with de novo DLBCL.In this phase 2, single-arm study, unfit or frail patients with de novo DLBCL aged 75 years or older were enrolled at Shanghai Ruijin Hospital, Shanghai, China. During the induction phase from cycle 1 to 6, 560 mg ibrutinib was given orally daily throughout each 21-day treatment cycle, 375 mg/m2 rituximab was given intravenously on day 1, and 25 mg lenalidomide was given orally daily from day 1 to 10 in each cycle. Patients who had a complete response after induction were given another 6 cycles of lenalidomide maintenance (25 mg orally daily from day 1 to 10 every 21 days from cycle 7 to 12). The primary endpoint was complete response rate after 6 cycles or at the end of the induction treatment. This trial is registered with ClinicalTrials.gov, NCT03949062.Between May 15, 2019, and May 8, 2020, a total of 30 patients were enrolled. The end of induction complete response rate was 56·7% (95% CI 37·4-74·5), and overall response rate was 66·7% (95% CI 47·2-82·7). With a median follow-up of 27·6 months (IQR 23·9-29·6), the 2-year progression-free survival rate was 53·3% (95% CI 34·3-69·1) and the 2-year overall survival rate was 66·7% (95% CI 46·9-80·5). The main grade 3-4 haematological adverse events were neutropenia (seven patients [23%]), thrombocytopenia (three patients [10%]), and anaemia (two patients [7%]). The most common grade 3-4 non-haematological adverse event was pulmonary infection (seven patients [23%]). Atrial fibrillation was observed in three (10%) patients, including one grade 2 and two grade 3.A chemotherapy-free iR2 regimen is clinically effective and safe and warrants further investigation in phase 3 trials as first-line treatment in older adult patients with DLBCL.National Natural Science Foundation of China, Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support, Clinical Research Plan of Shanghai Hospital Development Center, and Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
打打应助la采纳,获得10
1秒前
1秒前
量子星尘发布了新的文献求助10
1秒前
1秒前
养乐多完成签到,获得积分10
2秒前
2秒前
赘婿应助啦啦啦采纳,获得10
3秒前
3秒前
小坤同学发布了新的文献求助200
3秒前
3秒前
秋天完成签到,获得积分10
4秒前
炜豪发布了新的文献求助10
4秒前
4秒前
樱悼柳雪发布了新的文献求助10
4秒前
JamesPei应助曹博采纳,获得10
4秒前
yu发布了新的文献求助10
5秒前
cllg完成签到,获得积分10
6秒前
笨笨支付宝完成签到,获得积分10
6秒前
赫灵竹完成签到,获得积分10
6秒前
mayamaya完成签到,获得积分10
6秒前
小黑球发布了新的文献求助10
6秒前
6秒前
尊敬雪萍完成签到,获得积分10
6秒前
dou发布了新的文献求助10
6秒前
苗大楚完成签到 ,获得积分10
6秒前
李健的粉丝团团长应助axn采纳,获得10
7秒前
萝卜酸辣粉完成签到,获得积分10
7秒前
7秒前
科研通AI2S应助Xiaoguo采纳,获得10
8秒前
mzf发布了新的文献求助10
8秒前
8秒前
9秒前
myers完成签到,获得积分10
9秒前
打打应助是漏漏呀采纳,获得10
9秒前
Orange发布了新的文献求助10
10秒前
SciGPT应助tao采纳,获得10
10秒前
10秒前
龙金兴完成签到 ,获得积分10
11秒前
Jy完成签到 ,获得积分10
11秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974844
求助须知:如何正确求助?哪些是违规求助? 3519270
关于积分的说明 11197844
捐赠科研通 3255496
什么是DOI,文献DOI怎么找? 1797791
邀请新用户注册赠送积分活动 877187
科研通“疑难数据库(出版商)”最低求助积分说明 806202